Skip to content

Study · Randomized controlled trial · 2025

3 results

Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6.

Apperloo EM, Cherney DZI, Kuhlman AB, Mann JFE, Rasmussen S, Rossing P, Tuttle KR, Vrhnjak B, Heerspink HJL

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association1 Feb 2025Cited by 15 (Europe PMC)

PMID38955363 (opens in a new tab)PMCIDPMC11792646 (opens in a new tab)DOI10.1093/ndt/gfae150 (opens in a new tab)PepBankPUB-38955363
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and high cardiovascular risk, semaglutide slowed eGFR decline versus placebo in pooled SUSTAIN 6 and PIONEER 6 data (difference 0.59 mL/min/1.73 m2/year).

    In plain wordsIn adults with type 2 diabetes and high heart risk, semaglutide slowed the yearly fall in kidney filtration compared with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseeGFR slope, pooled SUSTAIN 6 and PIONEER 6
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    eGFR slope difference
    0.59 mL/min/1.73 m2/year
    pooled analysis

    Source sentences

    Summary
    favored semaglutide versus placebo in the pooled analysis [0.59 (0.29; 0.89) mL/min/1.73 m2/year]
    1 context sentence
    Summary · context
    This post hoc analysis explored the effects of semaglutide on estimated glomerular filtration (eGFR) slope by baseline glycemic control, blood pressure (BP), body mass index (BMI) and albuminuria status in people with type 2 diabetes and high cardiovascular risk.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and high cardiovascular risk in SUSTAIN 6, semaglutide slowed eGFR decline versus placebo (difference 0.60 mL/min/1.73 m2/year).

    In plain wordsIn adults with type 2 diabetes and high heart risk in SUSTAIN 6, semaglutide slowed the yearly fall in kidney filtration compared with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseeGFR slope, SUSTAIN 6
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    eGFR slope difference
    0.6 mL/min/1.73 m2/year
    SUSTAIN 6

    Source sentences

    Summary
    favored semaglutide versus placebo
    2 context sentences
    Summary · context
    in SUSTAIN 6 [0.60 (0.24; 0.96) mL/min/1.73 m2/year]
    Summary · context
    This post hoc analysis explored the effects of semaglutide on estimated glomerular filtration (eGFR) slope by baseline glycemic control, blood pressure (BP), body mass index (BMI) and albuminuria status in people with type 2 diabetes and high cardiovascular risk.
  3. 03HumanRandomized controlled trialEfficacy outcome

    The eGFR slope benefit of semaglutide versus placebo was consistent across baseline HbA1c, blood pressure, BMI and albuminuria subgroups (all P-interaction >.5).

    In plain wordsThe kidney benefit of semaglutide over placebo was similar whatever the starting HbA1c, blood pressure, weight or albumin level.

    Peptide
    Semaglutide
    Outcome
    No significant changeeGFR slope benefit across baseline subgroups
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the absolute benefit was consistent across all HbA1c, BP, BMI and UACR subgroups (all P-interaction >.5).
    1 context sentence
    Summary · context
    This post hoc analysis explored the effects of semaglutide on estimated glomerular filtration (eGFR) slope by baseline glycemic control, blood pressure (BP), body mass index (BMI) and albuminuria status in people with type 2 diabetes and high cardiovascular risk.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.